// App-Quantinova.ai

: CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Simon J. Crabb

Principal Investigators

  • Ding-Wei Ye

  • Hirotsugu Uemura

  • Thomas Morris

  • Christopher Gresty

  • Jill Logan

  • Claire Rooney

  • Andrew Foxley

  • Michael Anthony Carducci

Medical Centers

  • Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Johns Hopkins, Baltimore, MD

  • Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  • Fudan University Shanghai Cancer Center, Shanghai, China

Locations

  • China

  • Japan

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Prednisolone

  • Prednisone

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02121639

  • NCT05348577

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved